For the first time in 50 years new oral anticoagulants of proven efficacy and with acceptable safety profiles are available for patients with atrial fibrillation and venous thromboembolism. Here is a brief overview of the benefits and possible disadvantages of using these drugs.
KEYWORDS Dabigatran, rivaroxaban, apixaban, anticoagulation, atrial fibrillation, venous thromboembolism
DECLARATIONS OF INTERESTS No conflicts of interest declared.
